Category: prescription drugs

When an Anti-Vaccine Activist Runs for President

Robert F. Kennedy Jr.’s official entry into the presidential race poses a thorny challenge for journalists: how to cover a candidate who’s opposed to vaccines without amplifying misinformation. And South Carolina becomes the latest state in the South to ban abortion after roughly six weeks of pregnancy. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KFF Health News senior correspondent Aneri Pattani about her project to track the billions of dollars coming from opioid makers to settle lawsuits.

About 1 in 20 People with Private Insurance Received Services that Could be Affected by a District Court Ruling Limiting the ACA’s Preventive Services Mandate

A new KFF analysis finds about 1 in 20 privately insured people (5.7%) received at least one ACA preventive service or drug that could be affected by a now-stayed U.S. District Court ruling in Braidwood Management v. Becerra, which found the Affordable…

This Panel Will Decide Whose Medicine to Make Affordable. Its Choice Will Be Tricky.

Colorado’s new Prescription Drug Affordability Board could cap what health plans and consumers pay for certain medications starting next year. The process will pit patient groups against one another.

A More Aggressive FTC Is Starting to Target Drug Mergers and Industry Middlemen

Industry analysts are skeptical that Federal Trade Commission Chair Lina Khan can win her first fight against a drug industry merger. It will be reviewed by a judge appointed by then-President Donald Trump.

Are US Prescription Drug Prices 10 Times Those of Other Nations? Only Sometimes

Sen. Bernie Sanders’ broad statement that some U.S. drug prices are 10 times those of other nations doesn’t paint the full picture. Studies we examined generally found that U.S. prices were 2 to 4 times those in other countries, not 10.

PBMs, the Brokers Who Control Drug Prices, Finally Get Washington’s Attention

Drugmakers, pharmacies, and physicians blame pharmacy benefit managers for high drug prices. Congress is finally on board, too, but will it matter?

California Confronts Overdose Epidemic Among Former Prison Inmates

Individuals newly released from prison are 40 times as likely to die of opioid overdoses than members of the general population, researchers say. In response, California corrections officials aim to arm departing inmates with an antidote that can be used to reverse the effects of opioid poisoning.

Will They or Won’t They (Block the Abortion Pill)?

The Supreme Court is considering the future of the abortion pill mifepristone, after GenBioPro sued the FDA over limitations that effectively block generic production of the drug, a major part of the market. Congress is considering proposals that would impose Medicaid work requirements, crack down on pharmacy benefit managers, and more. And President Joe Biden moved to expand health coverage to young immigrants known as “Dreamers.” Rachel Cohrs of Stat, Sandhya Raman of CQ Roll Call, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KFF Health News’ Mary Agnes Carey to discuss these issues and more.

The Drug Company That Prospered Without Creating Any Drugs

Horizon Therapeutics, which Amgen is acquiring for about $28 billion, grew large by snapping up cheap drugs from other companies, marketing them to perfection, and jacking up prices.

Truly Random Drug Testing: ADHD Patients Face Uneven Urine Screens and, Sometimes, Stigma

Doctors have no national standards on when to order urine tests to check whether adult ADHD patients are properly taking their prescription stimulants. Some patients are subjected to much more frequent testing than others.